New drug trial aims to slow kidney damage in IgA nephropathy
NCT ID NCT07474636
Summary
This study is testing whether an experimental capsule called HS-10542 can help control IgA nephropathy, a kidney disease where protein leaks into urine. About 90 adults with confirmed IgA nephropathy will take either the drug or a placebo for 24 weeks to see if it safely reduces protein in their urine. Researchers are testing different doses to find the most effective one with acceptable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.